Barings’s NovoCure NVCR Stock Holding History

Barings’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,901	Closed	-$202K	–	277
2022 Q2	$202K	Buy	+2,901	New	+$219K	0.01%	309

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barings's NVCR Position: Q3 2022 in Review

Barings sold out of NovoCure (NVCR) in Q3 2022, closing a stake of 2,901 shares — an estimated $202K sold.

Barings first reported a position in NVCR in Q2 2022 and held it in 1 quarter. The position peaked at $202K in Q2 2022. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Barings reported no remaining NovoCure position as of Q3 2022 after selling out during the quarter.
Barings sold 2,901 NovoCure shares in Q3 2022, an estimated $202K.
Barings first reported a position in NovoCure in Q2 2022 and held it in 1 quarter.
Barings's NovoCure position peaked at $202K in Q2 2022.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Barings's 13F filing for Q3 2022, filed 14 Nov 2022.